Wnt pathway activation and ABCB1 expression account for attenuation of Proteasome inhibitor-mediated apoptosis in multidrug-resistant cancer cells

References

• Goldman ID. Transport energetics of the folic acid analogue, methotrexate, in L1210 leukemia cells. Enhanced accumulation by metabolic inhibitors. J Biol Chem 1969; 244: 3779-85; PMID:5805398
   PubMed Web of Science ®Google Scholar
• Higgins CF. Multiple molecular mechanisms for multidrug resistance transporters. Nature 2007; 446: 749-57; PMID:17429392; http://dx.doi.org/10.1038/nature05630
   PubMed Web of Science ®Google Scholar
• Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61, 3071-76; PMID:11306489
   PubMed Web of Science ®Google Scholar
• Richardson PG, Anderson KC. Bortezomib: a novel therapy approved for multiple myeloma. Clin Adv Hematol Onco 2003; 1: 596-600.
   PubMedGoogle Scholar
• Bross PF, Kane R, Farrell AT, Abraham S, Benson K, Brower ME, Bradley S, Gobburu JV, Goheer A, Lee SL, et al. Approval summary for bortezomib for injection in the treatment of multiple myeloma. Clin Cancer Res 2004; 10: 3954-64; PMID:15217925; http://dx.doi.org/10.1158/1078-0432.CCR-03-0781
   PubMed Web of Science ®Google Scholar
• Cortes J, Thomas D, Koller C, Giles F, Estey E, Faderl S, Garcia-Manero G, McConkey D, Ruiz SL, Guerciolini R, et al. Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin Cancer Res 2004; 10: 3371-76; PMID:15161691; http://dx.doi.org/10.1158/1078-0432.CCR-03-0508
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Jacobus S, Vesole DH, Callandar N, Fonseca R, Greipp PR. Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial. Leukemia 2010; 24: 1406-11; PMID:20535147; http://dx.doi.org/10.1038/leu.2010.129
   PubMed Web of Science ®Google Scholar
• Chauhan D, Catley L, Li G, Podar K, Hideshima T, Velankar M, Mitsiades C, Mitsiades N, Yasui H, Letai A, et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 2005; 8: 407-19; PMID:16286248; http://dx.doi.org/10.1016/j.ccr.2005.10.013
   PubMed Web of Science ®Google Scholar
• Hideshima T, Chauhan D, Richardson P, Anderson KC. Identification and validation of novel therapeutic targets for multiple myeloma. J Clin Oncol 2005; 23: 6345-50; PMID:16155018; http://dx.doi.org/10.1200/JCO.2005.05.024
   PubMed Web of Science ®Google Scholar
• Oerlemans R, Franke NE, Assaraf YG, Cloos J, van Zantwijk I, Berkers CR, Scheffer GL, Debipersad K, Vojtekova K, Lemos C, et al. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood 2008; 112: 2489-99; PMID:18565852; http://dx.doi.org/10.1182/blood-2007-08-104950
   PubMed Web of Science ®Google Scholar
• Nakamura T, Tanaka K, Matsunobu T, Okada T, Nakatani F, Sakimura R, Hanada M, Iwamoto Y. The mechanism of cross-resistance to proteasome inhibitor bortezomib and overcoming resistance in Ewing's family tumor cells. Int J Oncol 2007; 31: 803-11; PMID:17786311
   PubMed Web of Science ®Google Scholar
• O'Connor R, Ooi MG, Meiller J, Jakubikova J, Klippel S, Delmore J, Richardson P, Anderson K, Clynes M, Mitsiades CS, et al. The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias. Cancer Chemother Pharmacol 2013; 71: 1357-68; PMID:23589314; http://dx.doi.org/10.1007/s00280-013-2136-7
   PubMed Web of Science ®Google Scholar
• Rumpold H, Salvador C, Wolf AM, Tilg H, Gastl G, Wolf D. Knockdown of Pgp resensitizes leukemic cells to proteasome inhibitors. Biochem Biophys Res Commun 2007; 361: 549-54; PMID:17662692; http://dx.doi.org/10.1016/j.bbrc.2007.07.049
   PubMed Web of Science ®Google Scholar
• Fujita T, Washio K, Takabatake D, Takahashi H, Yoshitomi S, Tsukuda K, Ishibe Y, Ogasawara Y, Doihara H, Shimizu N. Proteasome inhibitors can alter the signaling pathways and attenuate the P-glycoprotein-mediated multidrug resistance. Int J Cancer 2005; 117: 670-82; PMID:15945097; http://dx.doi.org/10.1002/ijc.21063
   PubMed Web of Science ®Google Scholar
• Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61, 3071-6; PMID:11306489
   PubMed Web of Science ®Google Scholar
• Yamada T, Takaoka AS, Naishiro Y, Hayashi R, Maruyama K, Maesawa C, Ochiai A, Hirohashi S. Transactivation of the multidrug resistance 1 gene by T-cell factor 4/beta-catenin complex in early colorectal carcinogenesis. Cancer Res 2000; 60: 4761-6; PMID:10987283
   PubMed Web of Science ®Google Scholar
• Labialle S, Gayet L, Marthinet E, Rigal D, Baggetto LG. Transcriptional regulators of the human multidrug resistance 1 gene: recent views. Biochem Pharmacol 2002; 64: 943-8; PMID:12213590; http://dx.doi.org/10.1016/S0006-2952(02)01156-5
   PubMed Web of Science ®Google Scholar
• Luu HH, Zhang R, Haydon RC, Rayburn E, Kang Q, Si W, Park JK, Wang H, Peng Y, Jiang W, et al. Wnt/beta-catenin signaling pathway as a novel cancer drug target. Curr Cancer Drug Targets 2004; 4: 653-71; PMID:15578921; http://dx.doi.org/10.2174/1568009043332709
   PubMed Web of Science ®Google Scholar
• Liang J, Slingerland JM. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2003; 2: 339-45; PMID:12851486; http://dx.doi.org/10.4161/cc.2.4.433
   PubMed Web of Science ®Google Scholar
• Wagenknecht B, Hermisson M, Eitel K, Weller M. Proteasome inhibitors induce p53/p21-independent apoptosis in human glioma cells. Cell Physiol Biochem 1999; 9: 117-25; PMID:10494025; http://dx.doi.org/10.1159/000016308
   PubMed Web of Science ®Google Scholar
• Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, Vogelstein B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998; 282: 1497-501; PMID:9822382; http://dx.doi.org/10.1126/science.282.5393.1497
   PubMed Web of Science ®Google Scholar
• Kim OH, Lim JH, Woo KJ, Kim YH, Jin IN, Han ST, Park JW, Kwon TK. Influence of p53 and p21Waf1 expression on G2/M phase arrest of colorectal carcinoma HCT116 cells to proteasome inhibitors. Int J Oncol 2004; 24: 935-41; PMID:15010833
   PubMed Web of Science ®Google Scholar
• Harker WG, Sikic BI. Multidrug (pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line MES-SA. Cancer Res 1985; 45: 4091-6; PMID:4028002
   PubMed Web of Science ®Google Scholar
• Calcagno AM, Ambudkar SV. Molecular mechanisms of drug resistance in single-step and multi-step drug-selected cancer cells. Methods Mol Biol 2010; 596: 77-93; PMID:19949921; http://dx.doi.org/10.1007/978-1-60761-416-6_5
   PubMedGoogle Scholar
• Calcagno AM, Salcido CD, Gillet JP, Wu CP, Fostel JM, Mumau MD, Gottesman MM, Varticovski L, Ambudkar SV. Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. J Natl Cancer Inst 2010; 102: 1637-52; PMID:20935265; http://dx.doi.org/10.1093/jnci/djq361
   PubMed Web of Science ®Google Scholar
• Lauricella M, D'Anneo A, Giuliano M, Calvaruso G, Emanuele S, Vento R, Tesoriere G. Induction of apoptosis in human osteosarcoma Saos-2 cells by the proteasome inhibitor MG132 and the protective effect of pRb. Cell Death Differ 2003; 10: 930-2; PMID:12868001; http://dx.doi.org/10.1038/sj.cdd.4401251
   PubMed Web of Science ®Google Scholar
• Yuan B-Z, Chapman JA, Reynolds SH. Proteasome inhibitor MG132 induces apoptosis and inhibits invasion of human malignant pleural mesothelioma cells. Transl Oncol 2008; 1: 129-14; PMID:18795123; http://dx.doi.org/10.1593/tlo.08133
   PubMed Web of Science ®Google Scholar
• Corrêa S, Binato R, Du Rocher B, Castelo-Branco MT, Pizzatti L, Abdelhay E. Wnt/β-catenin pathway regulates ABCB1 transcription in chronic myeloid leukemia. BMC Cancer 2012; 12: 303; http://dx.doi.org/10.1186/1471-2407-12-303
   PubMed Web of Science ®Google Scholar
• Sharma RC, Inoue S, Roitelman J, Schimke RT, Simoni RD. Peptide transport by the multidrug resistance pump. J Biol Chem 1992; 267: 5731-4; PMID:1348245
   PubMed Web of Science ®Google Scholar
• Minderman H, Zhou Y, O'Loughlin KL, Baer MR. Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status. Cancer Chemother Pharmacol 2007; 60: 245-55; PMID:17096161; http://dx.doi.org/10.1007/s00280-006-0367-6
   PubMed Web of Science ®Google Scholar
• Verbrugge SE, Assaraf YG, Dijkmans BA, Scheffer GL, Al M, den Uyl D, Oerlemans R, Chan ET, Kirk CJ, Peters GJ, van der Heijden JW, et al. Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno) proteasome inhibitors inmononuclear blood cells from patients with rheumatoid arthritis. J Pharmacol Exp Ther 2012; 341: 174-82; PMID:22235146; http://dx.doi.org/10.1124/jpet.111.187542
   PubMed Web of Science ®Google Scholar
• Zheng B, Zhou R, Gong Y, Yang X, Shan Q. Proteasome inhibitor bortezomib overcomes P-gp-mediated multidrug resistance in resistant leukemic cell lines. Int J Lab Hematol 2012; 34: 237-47; PMID:22145750; http://dx.doi.org/10.1111/j.1751-553X.2011.01384.x
   PubMed Web of Science ®Google Scholar
• Cervello M, Giannitrapani L, La Rosa M, Notarbartolo M, Labbozzetta M, Poma P, Montalto G, D'Alessandro N. Induction of apoptosis by the proteasome inhibitor MG132 in human HCC cells: Possible correlation with specific caspase-dependent cleavage of beta-catenin and inhibition of beta-catenin-mediated transactivation. Int J Mol Med 2004; 13, 741-8; PMID:15067380
   PubMed Web of Science ®Google Scholar
• Conzen SD, Gottlob K, Kandel ES, Khanduri P, Wagner AJ, O'Leary M, Hay N. Induction of cell cycle progression and acceleration of apoptosis are two separable functions of c-Myc: transrepression correlates with acceleration of apoptosis. Mol Cell Biol 2000; 20: 6008-18; PMID:10913183; http://dx.doi.org/10.1128/MCB.20.16.6008-6018.2000
   PubMed Web of Science ®Google Scholar
• Hung TH, Chen CM, Tseng CP, Shen CJ, Wang HL, Choo KB, Chong KY. FZD1 activates protein kinase C delta-mediated drug-resistance in multidrug-resistant MES-SA/Dx5 cancer cells. Int J Biochem Cell Biol 2014; 53: 55-65; PMID:24814288; http://dx.doi.org/10.1016/j.biocel.2014.04.011
   PubMed Web of Science ®Google Scholar
• Huang CL, Cheng JC, Kitajima K, Nakano T, Yeh CF, Chong KY, Tseng CP. Disabled-2 is required for mesoderm differentiation of murine embryonic stem cells. J Cell Physiol. 2010; 225: 92-105; PMID:20648627; http://dx.doi.org/10.1002/jcp.22200
   PubMed Web of Science ®Google Scholar
• Hsu HT, Liu PC, Ku SY, Jung KC, Hong YR, Kao C, Wang C. Beta-catenin control of T-cell transcription factor 4 (Tcf4) importation from the cytoplasm to the nucleus contributes to Tcf4-mediated transcription in 293 cells. Biochem Biophys Res Commun 2006; 343: 893-8; PMID:16564030; http://dx.doi.org/10.1016/j.bbrc.2006.02.193
   PubMed Web of Science ®Google Scholar
• Chong KY, Lai CC, Su CY. Inducible and constitutive HSP70s confer synergistic resistance against metabolic challenges. Biochem Biophys Res Commun. 2013; 430: 774-9; PMID:23206709; http://dx.doi.org/10.1016/j.bbrc.2012.11.072
   PubMed Web of Science ®Google Scholar
• Hung TH, Hsu SC, Choo KB, Tseng CP. Chen TC, Lan YW, Huang TT, Lai HC, Chen CM, Chong KY. Wnt5A regulates ABCB1 expression in multidrug-resistant cancer cells through activation of the non-canonical PKA/β-catenin pathway. Oncotarget 2014; 5: 12273-90.
   Google Scholar